Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Gains from Sales and Divestitures (2020 - 2025)

Revolution Medicines has reported Gains from Sales and Divestitures over the past 6 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Gains from Sales and Divestitures at $1.3 million for Q4 2025, up 33.43% from a year ago — trailing twelve months through Dec 2025 was $1.3 million (up 33.43% YoY), and the annual figure for FY2025 was $1.3 million, up 33.43%.
  • Gains from Sales and Divestitures for Q4 2025 was $1.3 million at Revolution Medicines, up from $978467.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for RVMD hit a ceiling of $1.3 million in Q4 2025 and a floor of $1798.0 in Q1 2021.
  • Median Gains from Sales and Divestitures over the past 5 years was $265839.5 (2023), compared with a mean of $386627.2.
  • Biggest five-year swings in Gains from Sales and Divestitures: soared 4540.69% in 2021 and later soared 33.43% in 2025.
  • Revolution Medicines' Gains from Sales and Divestitures stood at $78010.0 in 2021, then surged by 257.45% to $278848.0 in 2022, then soared by 106.91% to $576974.0 in 2023, then skyrocketed by 75.27% to $1.0 million in 2024, then surged by 33.43% to $1.3 million in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $1.3 million (Q4 2025), $978467.0 (Q3 2025), and $633511.0 (Q2 2025) per Business Quant data.